 <h1>Methotrimeprazine Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to methotrimeprazine: intramuscular solution</i></p><h3>General</h3><p>The most commonly reported side effects included dry mouth, somnolence, hypotension, and convulsions.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Heat stroke, hypotension, QT prolongation</p><p><b>Uncommon</b> (0.1% to 1%): Tachycardia, venous thromboembolism/fatal venous thromboembolism</p><p><b>Rare</b> (0.01% to 0.1%): Cardiac arrest, cardiac rhythm disturbances, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia</p><p><b>Frequency not reported</b>: Atrial arrhythmias, atrioventricular (AV) block, cardiac arrhythmias, deep vein thrombosis, ECG changes, orthostatic hypotension, postural hypotension, ST depression, sudden cardiac death, Torsade de pointes, T-wave changes, U-wave changes<sup>[Ref]</sup></p><p>Heat stroke occurred in hot and humid conditions.</p><p></p><p>Hypotension occurred with use, especially in older patients.</p><p></p><p>Orthostatic hypotension occurred with high initial oral doses or with initial parenteral doses.</p><p></p><p>Patients who develop Torsade de pointes should discontinue treatment and should be given therapy to correct imbalances (e.g., acid base disturbances, electrolyte imbalances, hypoxia).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Drowsiness, sedation, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Convulsions, parkinsonism</p><p><b>Rare</b> (0.01% to 0.1%): Extrapyramidal effects</p><p><b>Frequency not reported</b>: Akathisia, akinesia with/without hypertonia, anticholinergic syndrome, early dyskinesia, epileptic seizures, hyperkinetic-hypertonic movements, motor excitation, neuroleptic malignant syndrome, oculogyric crises, spasmodic torticollis, tardive dyskinesia, trismus<sup>[Ref]</sup></p><p>Drowsiness, sedation, and/or somnolence usually occurred early in treatment, but gradually disappeared after the first few weeks and/or with a dose adjustment.</p><p></p><p>Extrapyramidal syndrome includes akathisia, akinesia with/without hypertonia (partially relieved by antiparkinsonian agents), hyperkinetic-hypertonic movements, and/or motor excitation.  Extrapyramidal effects typically occurred after prolonged, high-dose treatment; the effect was treated with reductions in dose or with the addition of an antiparkinsonian agent.</p><p></p><p>Oculogyric crises, spasmodic torticollis, and trismus occurred with early dyskinesia.</p><p></p><p>Parkinsonism was prolonged with higher doses.</p><p></p><p>Tardive dyskinesia occurred with prolonged use, may recur if the neuroleptic is discontinued, and may resolve upon rechallenge or with an increase in dose.  Antiparkinsonian agents may cause symptom exacerbation.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Severe constipation may occur with treatment, and laxatives may be needed to treat the condition.  Patients should report any new or worsening constipation to their healthcare provider.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Dry mouth</p><p><b>Uncommon</b> (0.1% to 1%): Constipation/severe constipation</p><p><b>Very rare</b> (less than 0.01%): Fatal necrotizing enterocolitis/necrotizing enterocolitis</p><p><b>Frequency not reported</b>: Paralytic ileus<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia</p><p><b>Frequency not reported</b>: Neonatal drug withdrawal syndrome, sudden death/unexplained sudden death, thermoregulation disorders<sup>[Ref]</sup></p><p>Asthenia usually occurred early in treatment, but gradually disappeared after the first few weeks.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Agranulocytosis, raised erythrocyte sedimentation rate (ESR)</p><p><b>Frequency not reported</b>: Granulocytopenia, leukocytopenia, neutropenia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions/allergic dermatitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Photosensitivity/photosensitivity reaction<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Urinary retention</p><p><b>Very rare</b> (less than 0.01%): Priapism</p><p><b>Frequency not reported</b>: Amenorrhea, galactorrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Weight gain usually occurred in patients receiving prolonged, high-dose treatment.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Weight gain</p><p><b>Frequency not reported</b>: Acid base disturbances, diabetic ketoacidosis, electrolyte abnormalities, glucose intolerance/impaired glucose tolerance, hyperglycemia, hyponatremia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Cholestatic jaundice without liver damage, jaundice</p><p><b>Frequency not reported</b>: Cholestatic liver injury, hepatocellular liver injury, mixed liver injury<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety reactions, confusional state, delirium, frigidity, impotence, indifference, mood changes<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Gynecomastia, hyperprolactinemia, hypogonadism, syndrome of inappropriate antidiuretic hormone (SIADH) secretion<sup>[Ref]</sup></p><p>Hyperprolactinemia may result in amenorrhea, frigidity, galactorrhea, gynecomastia, and impotence.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Fatal pulmonary embolism/pulmonary embolism, hypoxia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Brown deposits in the anterior segment of the eye usually do not affect vision, and are caused by accumulation of the drug.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Accommodation disorder, brown deposits in the anterior segment of the eye<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Decreased bone mineral density<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Positive serology for antinuclear antibodies without clinical lupus erythematosus<sup>[Ref]</sup></p><p id="ref_1">1. New Zealand Medicines and Medical Devices Safety Authority "MEDSAFE. Available from: URL: http://www.medsafe.govt.nz/Profs/Datasheet/DSForm.asp."   ([2018, Aug 1]):</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Methoprazine (methotrimeprazine)." AA Pharma Inc, Vaughan , ON. </p><p id="ref_4">4. Cerner Multum,   Inc. "Canadian Product Information." O 0 (2015):</p><h2>More about methotrimeprazine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: phenothiazine antipsychotics</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>